Top related persons:
Top related locs:
Top related orgs:

Search resuls for: "Steve Klink"


3 mentions found


Philips Respironics announced on Monday that it would halt sales of all of its breathing machines in the United States after reaching a settlement with the Food and Drug Administration over continuing problems with the devices. Millions of the company’s ventilators and CPAP machines, used to ease breathing at night, were recalled after reports that they blew bits of foam and potentially toxic gases into consumers’ airways. Under the settlement, Philips said it would have to meet a list of standards in a “multiyear” plan before it could resume business in the United States. The company initially began the recall of millions of devices in June 2021 and paused sales of new sleep therapy machines to the United States, according to Steve Klink, a spokesman for Philips. cited the potential for serious injury or permanent impairment from the potentially cancer-causing chemicals emitted from the devices.
Persons: Philips Respironics, Philips, Steve Klink Organizations: Food and Drug Administration, Philips Locations: United States
Companies Koninklijke Philips NV FollowAMSTERDAM, Sept 7 (Reuters) - Philips (PHG.AS) said on Thursday it has reached a settlement to resolve one category of legal claims against it following a major recall of the Dutch medical equipment maker's sleep apnea and respiratory devices. The company had taken a 575 million euro ($615.48 million) provision in the first quarter of 2023 against estimated costs for economic loss claims. The company still faces other legal actions over the recall, including personal injury claims, as well as an investigation by the U.S. Department of Justice. However, the lawyers said in a joint statement they would continue to pursue personal injury and other claims against the company. "We are confident in these claims and we look forward to holding Philips accountable for the physical harm they caused patients," they said.
Persons: Philips, Steve Klink, Toby Sterling, Tassilo Hummel, Sudip Kar, Gupta, Susan Fenton, David Evans Organizations: Koninklijke Philips NV, Philips, U.S . Department of Justice, U.S . Food, Drugs Administration, Thomson Locations: AMSTERDAM
AMSTERDAM, Oct 12 (Reuters) - Dutch health technology company Philips (PHG.AS) said on Wednesday its third-quarter core profit would drop around 60%, and it flagged a charge of 1.3 billion euros ($1.26 billion) on the value of its plagued sleep and respiratory care business. In a trade update, Philips said its comparable sales fell around 5% in the third quarter, as supply chain problems remained bigger than the company had anticipated. This was expected to have pushed adjusted earnings before interest, taxes and amortisation (EBITA) down to 210 million euros, or around 5% of sales, Philips said. Register now for FREE unlimited access to Reuters.com RegisterAdjusted EBITA was 512 million euros in the third quarter of 2021. Philips will publish its full third-quarter results on Oct. 24.
Total: 3